Dysregulation of SREBP2 induces BACE1 expression

Neurobiology of Disease

Volumn 44, Issue 1, 2011, Pages 116-124

  Mastrocola, Raffaella ^a   Guglielmotto, Michela ^a,b   Medana, Claudio ^a   Catalano, Maria Graziella ^a   Cutrupi, Santina ^a   Borghi, Roberta ^c   Tamagno, Elena ^a,b   Boccuzzi, Giuseppe ^a   Aragno, Manuela ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Neuroscience Institute of the Cavalieri Ottolenghi Foundation (NICO)   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Alzheimer's disease; BACE1; Cholesterol synthesis; High fat diet; SREBP2

Indexed keywords

BETA SECRETASE 1; CHOLESTEROL; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN METABOLISM; CHOLESTEROL METABOLISM; CONTROLLED STUDY; GENE OVEREXPRESSION; GLUCOSE TOLERANCE; HOMEOSTASIS; LIPID DIET; MALE; METABOLIC SYNDROME X; NERVE CELL STIMULATION; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT; REGULATORY MECHANISM; RISK ASSESSMENT;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BLOTTING, WESTERN; BODY WEIGHT; BRAIN; CELL LINE, TUMOR; CELL NUCLEUS; CHOLESTEROL, DIETARY; CHROMATIN IMMUNOPRECIPITATION; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOSOL; DIET; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE TEST; HYDROXYCHOLESTEROLS; INSULIN; LIPIDS; MALE; NEURONS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STEROL REGULATORY ELEMENT BINDING PROTEINS; TISSUE EXTRACTS;

EID: 79961126043     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.06.010     Document Type: Article

References (51)

1. Bach C., Gilch S., Rost R., Greenwood A.D., Horsch M., Hajj G.N., Brodesser S., Facius A., Schädler S., Sandhoff K., Beckers J., Leib-Mösch C., Schätzl H.M., Vorberg I. Prion-induced activation of cholesterogenic gene expression by SREBP2 in neuronal cells. J. Biol. Chem. 2009, 284:31260-31269.
2. Bengoechea-Alonso M.T., Ericsson J. SREBP in signal transduction: cholesterol metabolism and beyond. Curr. Opin. Cell Biol. 2007, 19:215-222.
3. Bi X., Liao G. Cholesterol in Niemann-Pick type C disease. Subcell. Biochem. 2010, 51:319-335.
4. Björkhem I. Do oxysterols control cholesterol homeostasis?. J. Clin. Invest. 2002, 110(6):725-730.
5. Bjorkhem I., Meaney S. Brain cholesterol: long secret life behind a barrier. Aterioscler. Tromb. Vasc. Biol. 2004, 24:806-815.
6. Björkhem I., Heverin M., Leoni V., Meaney S., Diczfalusy U. Oxysterols and Alzheimer's disease. Acta Neurol. Scand. Suppl. 2006, 185:43-49.
7. Block R.C., Dorsey E.R., Beck C.A., Brenna J.T., Shoulson I. Altered cholesterol and fatty acid metabolism in Huntington disease. J. Clin. Lipidol. 2010, 4:17-23.
8. Bourne K.Z., Ferrari D.C., Lange-Dohna C., Rossner S., Wood T.G., Perez-Polo J.R. Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J. Neurosci. Res. 2007, 85:1194-1204.
9. Bryleva E.Y., Rogers M.A., Chang C.C., Buen F., Harris B.T., Rousselet E., Seidah N.G., Oddo S., LaFerla F.M., Spencer T.A., Hickey W.F., Chang T.Y. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(7):3081-3086.
10. Buxbaum J.D., Cullen E.I., Friedhoff L.T. Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. Front. Biosci. 2002, 7:50-59.
11. Cordy J.M., Hussain I., Dingwall C., Hooper N.M., Turner A.J. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:11735-11740.
12. Deng J.Y., Huang J.P., Lu L.S., Hung L.M. Impairment of cardiac insulin signaling and myocardial contractile performance in high-cholesterol/fructose-fed rats. Am. J. Physiol. Heart Circ. Physiol. 2007, 293(2):H978-H987.
13. Dietschy J.M., Turley S.D. Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 2004, 45:1375-1397.
14. Friedhoff L.T., Cullen E.I., Geoghagen N.S., Buxbaum J.D. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. Int. J. Neuropsychopharmacol. 2001, 4(2):127-130.
15. Ghribi O., Larsen B., Schrag M., Herman M.M. High cholesterol content in neurons increases BACE, β-amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp. Neurol. 2006, 200(2):460-467.
16. Goldstein J.L., DeBose-Boyd R.A., Brown M.S. Protein sensors for membrane sterols. Cell 2006, 124:35-46.
17. Granholm A.C., Bimonte-Nelson H.A., Moore A.B., Nelson M.E., Freeman L.R., Sambamurti K. Effects of a saturated fat and high cholesterol diet on memory and hippocampal morphology in the middle-aged rat. J. Alzheimers Dis. 2008, 14(2):133-145.
18. Guglielmotto M., Aragno M., Tamagno E., Vercellinatto I., Visentin S., Medana C., Catalano M.G., Smith M.A., Perry G., Danni O., Boccuzzi G., Tabaton M. AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol Aging 2010, 10.1016/j.neurobiolaging.2010.05.026.
19. Haass C. Take five-BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J. 2004, 23:483-488.
20. Ho L., Qin W., Pompl P.N., Xiang Z., Wang J., Zhao Z., Peng Y., Cambareri G., Rocher A., Mobbs C.V., Hof P.R., Pasinetti G.M. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 2004, 18:902-904.
21. Hoyer S., Riederer P. Alzheimer disease-no target for statin treatment. A mini review. Neurochem. Res. 2007, 32(4-5):695-706.
22. Ishii K., Tokuda T., Matsushima T., Miya F., Shoji S., Ikeda S., Tamaoka A. Pravastatin at 10mg/day does not decrease plasma levels of either amyloid-beta (Abeta) 40 or Abeta 42 in humans. Neurosci. Lett. 2003, 350(3):161-164.
23. Kirsch C., Eckert G.P., Koudinov A.R., Müller W.E. Brain cholesterol, statins and Alzheimer's disease. Pharmacopsychiatry 2003, 36(Suppl. 2):S113-S119.
24. Kivipelto M., Solomon A. Cholesterol as a risk factor for Alzheimer's disease-epidemiological evidence. Acta Neurologica. Scandinavica. 2006, 114(185):50-57.
25. Koudinov A.R., Koudinova N.V. Cholesterol homeostasis failure as a unifying cause of synaptic degeneration. J. Neurol. Sci. 2005, 230:233-240.
26. Lütjohann D.A., Papassotiropoulos A., Bjorkhem I., Locatelli S., Bagli M., Oehring R.D., Schlegel U., Jessen F., Rao M.L., von Bergmann K., Heun R. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J. Lipid. Res. 2000, 41:195-198.
27. Michikawa M. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease?. J. Neurosci. Res. 2003, 72:141-146.
28. Pappolla M.A., Bryant-Thomas T.K., Herbert D., et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 2003, 61(2):199-205.
29. Parsons R.B., Austen B.M. Protein lipidation of BACE. Biochem. Soc. Trans. 2005, 33(Pt 5):1091-1093.
30. Parsons R.B., Subramaniam D., Austen B.M. A specific inhibitor of cholesterol biosynthesis, BM15.766, reduces the expression of beta-secretase and the production of amyloid-beta in vitro. J. Neurochem. 2007, 102(4):1276-1291.
31. Prasanthi J.R., Huls A., Thomasson S., Thompson A., Schommer E., Ghribi O. Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells. Mol. Neurodegener. 2009, 4:1.
32. Puglielli L., Konopka G., Pack-Chung E., Ingano L.A., Berezovska O., Hyman B.T., Chang T.Y., Tanzi R.E., Kovacs D.M. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell. Biol. 2001, 3:905-912.
33. Puglielli L., Tanzi R.E., Kovacs D.M. Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 2003, 6:345-351.
34. Raffai R.L., Weisgraber K.H. Cholesterol: from heart attacks to Alzheimer's disease. J. Lipid. Res. 2003, 44(8):1423-1430.
35. Refolo L.M., Pappolla M.A., Malester B., et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 2000, 7(4):321-331.
36. Rushworth J.V., Hooper N.M. Lipid rafts: linking Alzheimer's amyloid-β production, aggregation, and toxicity at neuronal membranes. Int. J. Alzheimers Dis. 2010, 2011:603052.
37. Sambamurti K., Kinsey R., Maloney B., Ge Y.-W., Lahiri D.K. Gene structure and organization of the human β-secretase (BACE) promoter. FASEB J. 2004, 18:1034-1036.
38. Serrano-Pozo A., Vega G.L., Lütjohann D., Locascio J.J., Tennis M.K., Deng A., Atri A., Hyman B.T., Irizarry M.C., Growdon J.H. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheimer Dis. Assoc. Disord. 2010, 24(3):220-226.
39. Shobab L.A., Hsiung G.Y., Feldman H.H. Cholesterol in Alzheimer's disease. Lancet Neurol. 2005, 4(12):841-852.
40. Simons M., Keller P., Dichgans J., Schulz J.B. Cholesterol and Alzheimer's disease: is there a link?. Neurology 2001, 57(6):1089-1093.
41. Solomon A., Kivipelto M., Wolozin B., Zhou J., Whitmer R.A. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement. Geriatr. Cogn. Disord. 2009, 28(1):75-80.
42. Tamagno E., Parola M., Bardini P., Piccini A., Borghi R., Guglielmotto M., Santoro G., Davit A., Danni O., Smith M.A., Perry G., Tabaton M. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J. Neurochem. 2005, 92:628-636.
43. Thirumangalakudi L., Prakasam A., Zhang R., et al. High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J. Neurochem. 2008, 106(1):475-485.
44. Tong X.K., Nicolakakis N., Fernandes P., Ongali B., Brouillette J., Quirion R., Hamel E. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiol. Dis. 2009, 35(3):406-414.
45. Ullrich C., Pirchl M., Humpel C. Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol. Cell. Neurosci. 2010, 45(4):408-417.
46. Vassar R. The beta-secretase, BACE: a prime drug target for Alzheimer's disease. J. Mol. Neurosci. 2001, 17:157-170.
47. Wang Y., Muneton S., Sjövall J., Jovanovic J.N., Griffiths W.J. The effect of 24S-hydroxycholesterol on cholesterol homeostasis in neurons: quantitative changes to the cortical neuron proteome. J. Proteome. Res. 2008, 7(4):1606-1614.
48. Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 2004, 41:7-10.
49. Xiong H., Callaghan D., Jones A., Walker D.G., Lue L.F., Beach T.G., Sue L.I., Woulfe J., Xu H., Stanimirovic D.B., Zhang W. Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol. Dis. 2008, 29:422-437.
50. Zandi P.P., Sparks D.L., Khachaturian A.S., Tschanz J., Norton M., Steinberg M., Welsh-Bohmer K.A., Breitner J.C. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch. Gen. Psychiatry. 2005, 62(2):217-224. Cache County Study investigators.
51. Zhang L., Bruce-Keller A.J., Dasuri K., Nguyen A.T., Liu Y., Keller J.N. Diet-induced metabolic disturbances as modulators of brain homeostasis. Biochim. Biophys. Acta. 2009, 1792:417-422.